NEW YORK (GenomeWeb News) — Ipsogen today said it has co-exclusively licensed a biomarker from Xenomics linked to acute myeloid leukemia in order to develop and sell tests for the disease.
Ipsogen’s diagnostics, which will be designed to stratify and monitor AML patients, will be based on NPM1 mutations that will integrate Ipsogen’s quantitative and standardized technology, including its FusionQuant and ProfileQuant tools, according to a statement.
"With this acute disease, physicians need a rapid assessment of patient prognosis for effective use of chemotherapy,” Xenomics CSO Samuil Umansky said in a statement.
He added that NPM1 “provides an excellent test for monitoring the minimal residual disease and patients in response to anti-tumor therapy.”
Financial terms of the agreement were not released.